Iron deprivation in cancer-potential therapeutic implications

Nutrients

Volumn 5, Issue 8, 2013, Pages 2836-2859

  Heath, Jessica L ^a   Weiss, Joshua M ^a   Lavau, Catherine P ^a   Wechsler, Daniel S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Chelation; Iron; Leukemia; Neuroblastoma; Ribonucleotide reductase

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 5 HYDROXYPICOLINALDEHYDE THIOSEMICARBAZONE; 6 TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE PROTEIN; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AROYLHYDRAZONE; CARBOPLATIN; CICLOPIROX; CICLOPIROXOLAMINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEFERASIROX; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4,4, DIMETHYL 3 THIOSEMICARBAZONE; ELTROMBOPAG; ETOPOSIDE; IRON CHELATING AGENT; MESSENGER RNA; MYC PROTEIN; PYRIDOXAL ISONICOTINOYL HYDRAZONE; TACHPYRIDINE; THIOSEMICARBAZONE DERIVATIVE; THIOTEPA; TRANSFERRIN RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE REGULATION; CELL METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; ESOPHAGUS CARCINOMA; GENE OVEREXPRESSION; GENETIC STABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRON ABSORPTION; IRON CHELATION; IRON DEFICIENCY; IRON DEPLETION; IRON METABOLISM; IRON OVERLOAD; LEUKEMIA; LUNG CANCER; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NEUROEPITHELIOMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THALASSEMIA; TREATMENT DURATION; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

EID: 84880834280     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu5082836     Document Type: Review

References (116)

1. Fuqua, B.K.; Vulpe, C.D.; Anderson, G.J. Intestinal iron absorption. J. Trace Elem. Med. Biol. 2012, 26, 115-119.
2. De Domenico, I.; Ward, D.M.; Langelier, C.; Vaughn, M.B.; Nemeth, E.; Sundquist, W.I.; Ganz, T.; Musci, G.; Kaplan, J. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol. Biol. Cell 2007, 18, 2569-2578.
3. Aisen, P. Transferrin receptor 1. Int. J. Biochem. Cell Biol. 2004, 36, 2137-2143.
4. Dautry-Varsat, A.; Ciechanover, A.; Lodish, H.F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA 1983, 80, 2258-2262.
5. Graf, E.; Mahoney, J.R.; Bryant, R.G.; Eaton, J.W. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J. Biol. Chem. 1984, 259, 3620-3624.
6. Cairo, G.; Recalcati, S. Iron-regulatory proteins: Molecular biology and pathophysiological implications. Expert Rev. Mol. Med. 2007, 9, 1-13.
7. Cairo, G.; Tacchini, L.; Pogliaghi, G.; Anzon, E.; Tomasi, A.; Bernelli-Zazzera, A. Induction of ferritin synthesis by oxidative stress. Transcriptional and post-transcriptional regulation by expansion of the -free iron pool. J. Biol. Chem. 1995, 270, 700-703.
8. Meyron-Holtz, E.G.; Ghosh, M.C.; Rouault, T.A. Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science 2004, 306, 2087-2090.
9. Recalcati, S.; Alberghini, A.; Campanella, A.; Gianelli, U.; de Camilli, E.; Conte, D.; Cairo, G. Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: Expression and regulation in hereditary hemochromatosis and iron deficiency. Haematologica 2006, 91, 303-310.
10. Kennedy, M.C.; Mende-Mueller, L.; Blondin, G.A.; Beinert, H. Purification and characterization of cytosolic aconitase from beef liver and its relationship to the iron-responsive element binding protein. Proc. Natl. Acad. Sci. USA 1992, 89, 11730-11734.
11. Elford, H.L.; Freese, M.; Passamani, E.; Morris, H.P. Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J. Biol. Chem. 1970, 245, 5228-5233.
12. Trinder, D.; Zak, O.; Aisen, P. Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology 1996, 23, 1512-1520.
13. Richardson, D.R.; Baker, E. The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta 1990, 1053, 1-12.
14. Dang, C.V. Myc on the path to cancer. Cell 2012, 149, 22-35.
15. Adhikary, S.; Eilers, M. Transcriptional regulation and transformation by myc proteins. Nat. Rev. Mol. Cell. Biol. 2005, 6, 635-645.
16. Dang, C.V. C-myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 1999, 19, 1-11.
17. Wu, K.J.; Polack, A.; Dalla-Favera, R. Coordinated regulation of iron-controlling genes, h-ferritin and irp2, by c-myc. Science 1999, 283, 676-679.
18. Graslund, A.; Ehrenberg, A.; Thelander, L. Characterization of the free radical of mammalian ribonucleotide reductase. J. Biol. Chem. 1982, 257, 5711-5715.
19. Green, D.A.; Antholine, W.E.; Wong, S.J.; Richardson, D.R.; Chitambar, C.R. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: Effect on the r2 subunit of ribonucleotide reductase. Clin. Cancer Res. 2001, 7, 3574-3579.
20. Shang, H.; Li, Q.; Feng, G.; Cui, Z. Molecular analysis and functions of p53r2 in zebrafish. Gene 2011, 475, 30-38.
21. Wei, P.P.; Tomter, A.B.; Rohr, A.K.; Andersson, K.K.; Solomon, E.I. Circular dichroism and magnetic circular dichroism studies of the active site of p53r2 from human and mouse: Iron binding and nature of the biferrous site relative to other ribonucleotide reductases. Biochemistry 2006, 45, 14043-14051.
22. Chen, D.; Li, M.; Luo, J.; Gu, W. Direct interactions between hif-1 αand mdm2 modulate p53 function. J. Biol. Chem. 2003, 278, 13595-13598.
23. Chen, K.; Albano, A.; Ho, A.; Keaney, J.F., Jr. Activation of p53 by oxidative stress involves platelet-derived growth factor-βreceptor-mediated ataxia telangiectasia mutated (atm) kinase activation. J. Biol. Chem. 2003, 278, 39527-39533.
24. Fukuchi, K.; Tomoyasu, S.; Watanabe, H.; Kaetsu, S.; Tsuruoka, N.; Gomi, K. Iron deprivation results in an increase in p53 expression. Biol. Chem. Hoppe-Seyler 1995, 376, 627-630.
25. Liang, S.X.; Richardson, D.R. The effect of potent iron chelators on the regulation of p53: Examination of the expression, localization and DNA-binding activity of p53 and the transactivation of waf1. Carcinogenesis 2003, 24, 1601-1614.
26. Saletta, F.; Suryo Rahmanto, Y.; Noulsri, E.; Richardson, D.R. Iron chelator-mediated alterations in gene expression: Identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol. Pharmacol. 2010, 77, 443-458.
27. Dongiovanni, P.; Fracanzani, A.L.; Cairo, G.; Megazzini, C.P.; Gatti, S.; Rametta, R.; Fargion, S.; Valenti, L. Iron-dependent regulation of mdm2 influences p53 activity and hepatic carcinogenesis. Am. J. Pathol. 2010, 176, 1006-1017.
28. Zhang, F.; Wang, W.; Tsuji, Y.; Torti, S.V.; Torti, F.M. Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J. Biol. Chem. 2008, 283, 33911-33918.
29. Weizer-Stern, O.; Adamsky, K.; Margalit, O.; Ashur-Fabian, O.; Givol, D.; Amariglio, N.; Rechavi, G. Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br. J. Haematol. 2007, 138, 253-262.
30. Campisi, J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001, 11, S27-S31.
31. Lagger, G.; Doetzlhofer, A.; Schuettengruber, B.; Haidweger, E.; Simboeck, E.; Tischler, J.; Chiocca, S.; Suske, G.; Rotheneder, H.; Wintersberger, E. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/waf1/cip1 gene. Mol. Cell. Biol. 2003, 23, 2669-2679.
32. Abbas, T.; Dutta, A. P21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9, 400-414.
33. Mitra, J.; Dai, C.Y.; Somasundaram, K.; El-Deiry, W.S.; Satyamoorthy, K.; Herlyn, M.; Enders, G.H. Induction of p21(waf1/cip1) and inhibition of cdk2 mediated by the tumor suppressor p16(ink4a). Mol. Cell. Biol. 1999, 19, 3916-3928.
34. Cayrol, C.; Knibiehler, M.; Ducommun, B. P21 binding to pcna causes g1 and g2 cell cycle arrest in p53-deficient cells. Oncogene 1998, 16, 311-320.
35. Stein, G.H.; Drullinger, L.F.; Soulard, A.; Dulic, V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell. Biol. 1999, 19, 2109-2117.
36. Zhang, Y.; Fujita, N.; Tsuruo, T. Caspase-mediated cleavage of p21waf1/cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999, 18, 1131-1138.
37. Kawata, S.; Ariumi, Y.; Shimotohno, K. P21(waf1/cip1/sdi1) prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human t-cell leukemia virus type 1-encoded tax. J. Virol. 2003, 77, 7291-7299.
38. Biankin, A.V.; Kench, J.G.; Dijkman, F.P.; Biankin, S.A.; Henshall, S.M. Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology 2003, 35, 14-24.
39. Weiss, R.H. P21waf1/cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003, 4, 425-429.
40. Gazitt, Y.; Reddy, S.V.; Alcantara, O.; Yang, J.; Boldt, D.H. A new molecular role for iron in regulation of cell cycling and differentiation of hl-60 human leukemia cells: Iron is required for transcription of p21(waf1/cip1) in cells induced by phorbol myristate acetate. J. Cell. Physiol. 2001, 187, 124-135.
41. Kramer, J.L.; Baltathakis, I.; Alcantara, O.S.; Boldt, D.H. Differentiation of functional dendritic cells and macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 (waf1/cip1) and requires iron. Br. J. Haematol. 2002, 117, 727-734.
42. Fu, D.; Richardson, D.R. Iron chelation and regulation of the cell cycle: 2 Mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21cip1/waf1 by iron depletion. Blood 2007, 110, 752-761.
43. Deshpande, A.; Sicinski, P.; Hinds, P.W. Cyclins and cdks in development and cancer: A perspective. Oncogene 2005, 24, 2909-2915.
44. Gao, J.; Richardson, D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, iv: The mechanisms involved in inhibiting cell-cycle progression. Blood 2001, 98, 842-850.
45. Kulp, K.S.; Green, S.L.; Vulliet, P.R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin d/cdk4 protein levels in asynchronous mda-mb-453 human breast cancer cells. Exp. Cell Res. 1996, 229, 60-68.
46. Nurtjahja-Tjendraputra, E.; Fu, D.; Phang, J.M.; Richardson, D.R. Iron chelation regulates cyclin d1 expression via the proteasome: A link to iron deficiency-mediated growth suppression. Blood 2007, 109, 4045-4054.
47. Masamha, C.P.; Benbrook, D.M. Cyclin d1 degradation is sufficient to induce g1 cell cycle arrest despite constitutive expression of cyclin e2 in ovarian cancer cells. Cancer Res. 2009, 69, 6565-6572.
48. Oexle, H.; Gnaiger, E.; Weiss, G. Iron-dependent changes in cellular energy metabolism: Influence on citric acid cycle and oxidative phosphorylation. Biochim. Biophys. Acta 1999, 1413, 99-107.
49. King, A.; Selak, M.A.; Gottlieb, E. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene 2006, 25, 4675-4682.
50. Wen, F.Q.; Jabbar, A.A.; Chen, Y.X.; Kazarian, T.; Patel, D.A.; Valentino, L.A. C-myc proto-oncogene expression in hemophilic synovitis: In vitro studies of the effects of iron and ceramide. Blood 2002, 100, 912-916.
51. Fan, L.; Iyer, J.; Zhu, S.; Frick, K.K.; Wada, R.K.; Eskenazi, A.E.; Berg, P.E.; Ikegaki, N.; Kennett, R.H.; Frantz, C.N. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res. 2001, 61, 1073-1079.
52. Shim, H.; Dolde, C.; Lewis, B.C.; Wu, C.S.; Dang, G.; Jungmann, R.A.; Dalla-Favera, R.; Dang, C.V. C-myc transactivation of ldh-a: Implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 1997, 94, 6658-6663.
53. Keith, B.; Johnson, R.S.; Simon, M.C. Hif1α and hif2α: Sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12, 9-22.
54. Talks, K.L.; Turley, H.; Gatter, K.C.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J.; Harris, A.L. The expression and distribution of the hypoxia-inducible factors hif-1α and hif-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 2000, 157, 411-421.
55. Lidgren, A.; Hedberg, Y.; Grankvist, K.; Rasmuson, T.; Vasko, J.; Ljungberg, B. The expression of hypoxia-inducible factor 1α is a favorable independent prognostic factor in renal cell carcinoma. Clin. Cancer Res. 2005, 11, 1129-1135.
56. Noguera, R.; Fredlund, E.; Piqueras, M.; Pietras, A.; Beckman, S.; Navarro, S.; Pahlman, S. Hif-1α and hif-2α are differentially regulated in vivo in neuroblastoma: High hif-1α correlates negatively to advanced clinical stage and tumor vascularization. Clin. Cancer Res. 2009, 15, 7130-7136.
57. Callapina, M.; Zhou, J.; Schnitzer, S.; Metzen, E.; Lohr, C.; Deitmer, J.W.; Brune, B. Nitric oxide reverses desferrioxamine-and hypoxia-evoked hif-1α accumulation-Implications for prolyl hydroxylase activity and iron. Exp. Cell Res. 2005, 306, 274-284.
58. Ellen, T.P.; Ke, Q.; Zhang, P.; Costa, M. Ndrg1, a growth and cancer related gene: Regulation of gene expression and function in normal and disease states. Carcinogenesis 2008, 29, 2-8.
59. Le, N.T.; Richardson, D.R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: A link between iron metabolism and proliferation. Blood 2004, 104, 2967-2975.
60. Guan, R.J.; Ford, H.L.; Fu, Y.; Li, Y.; Shaw, L.M.; Pardee, A.B. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000, 60, 749-755.
61. Bandyopadhyay, S.; Pai, S.K.; Gross, S.C.; Hirota, S.; Hosobe, S.; Miura, K.; Saito, K.; Commes, T.; Hayashi, S.; Watabe, M. The drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003, 63, 1731-1736.
62. Akiba, J.; Ogasawara, S.; Kawahara, A.; Nishida, N.; Sanada, S.; Moriya, F.; Kuwano, M.; Nakashima, O.; Yano, H. N-myc downstream regulated gene 1 (ndrg1)/cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma. Oncol. Rep. 2008, 20, 1329-1335.
63. Chua, M.S.; Sun, H.; Cheung, S.T.; Mason, V.; Higgins, J.; Ross, D.T.; Fan, S.T.; So, S. Overexpression of ndrg1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod. Pathol. 2007, 20, 76-83.
64. Blatt, J.; Stitely, S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res. 1987, 47, 1749-1750.
65. Foa, P.; Maiolo, A.T.; Lombardi, L.; Villa, L.; Polli, E.E. Inhibition of proliferation of human leukaemic cell populations by deferoxamine. Scand. J. Haematol. 1986, 36, 107-110.
66. Reddel, R.R.; Hedley, D.W.; Sutherland, R.L. Cell cycle effects of iron depletion on t-47d human breast cancer cells. Exp. Cell Res. 1985, 161, 277-284.
67. Hodges, Y.K.; Antholine, W.E.; Horwitz, L.D. Effect on ribonucleotide reductase of novel lipophilic iron chelators: The desferri-exochelins. Biochem. Biophys. Res. Commun. 2004, 315, 595-598.
68. Kalinowski, D.S.; Richardson, D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57, 547-583.
69. Keberle, H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. N. Y. Acad. Sci. 1964, 119, 758-768.
70. Pullarkat, V.; Sehgal, A.; Li, L.; Meng, Z.; Lin, A.; Forman, S.; Bhatia, R. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors. Leuk. Res. 2012, 36, 966-973.
71. Ohyashiki, J.H.; Kobayashi, C.; Hamamura, R.; Okabe, S.; Tauchi, T.; Ohyashiki, K. The oral iron chelator deferasirox represses signaling through the mtor in myeloid leukemia cells by enhancing expression of redd1. Cancer Sci. 2009, 100, 970-977.
72. Kim, J.L.; Kang, H.N.; Kang, M.H.; Yoo, Y.A.; Kim, J.S.; Choi, C.W. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase. Acta Haematol. 2011, 126, 241-245.
73. Chantrel-Groussard, K.; Gaboriau, F.; Pasdeloup, N.; Havouis, R.; Nick, H.; Pierre, J.L.; Brissot, P.; Lescoat, G. The new orally active iron chelator icl670a exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Eur. J. Pharmacol. 2006, 541, 129-137.
74. Torti, S.V.; Torti, F.M.; Whitman, S.P.; Brechbiel, M.W.; Park, G.; Planalp, R.P. Tumor cell cytotoxicity of a novel metal chelator. Blood 1998, 92, 1384-1389.
75. Samuni, A.M.; Krishna, M.C.; DeGraff, W.; Russo, A.; Planalp, R.P.; Brechbiel, M.W.; Mitchell, J.B. Mechanisms underlying the cytotoxic effects of tachpyr-A novel metal chelator. Biochim. Biophys. Acta 2002, 1571, 211-218.
76. Turner, J.; Koumenis, C.; Kute, T.E.; Planalp, R.P.; Brechbiel, M.W.; Beardsley, D.; Cody, B.; Brown, K.D.; Torti, F.M.; Torti, S.V. Tachpyridine, a metal chelator, induces g2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood 2005, 106, 3191-3199.
77. Baker, E.; Vitolo, M.L.; Webb, J. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem. Pharmacol. 1985, 34, 3011-3017.
78. Richardson, D.R.; Hefter, G.T.; May, P.M.; Webb, J.; Baker, E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol. Metals 1989, 2, 161-167.
79. Kim, B.K.; Huebers, H.A.; Finch, C.A. Effectiveness of oral iron chelators assayed in the rat. Am. J. Hematol. 1987, 24, 277-284.
80. Hershko, C.; Avramovici-Grisaru, S.; Link, G.; Gelfand, L.; Sarel, S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Clin. Med. 1981, 98, 99-108.
81. Becker, E.M.; Lovejoy, D.B.; Greer, J.M.; Watts, R.; Richardson, D.R. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (pkih) analogues as potent iron chelators and anti-tumour agents. Br. J. Pharmacol. 2003, 138, 819-830.
82. Thelander, L.; Graslund, A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. J. Biol. Chem. 1983, 258, 4063-4066.
83. DeConti, R.C.; Toftness, B.R.; Agrawal, K.C.; Tomchick, R.; Mead, J.A.; Bertino, J.R.; Sartorelli, A.C.; Creasey, W.A. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res. 1972, 32, 1455-1462.
84. Gojo, I.; Tidwell, M.L.; Greer, J.; Takebe, N.; Seiter, K.; Pochron, M.F.; Johnson, B.; Sznol, M.; Karp, J.E. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk. Res. 2007, 31, 1165-1173.
85. Yuan, J.; Lovejoy, D.B.; Richardson, D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment. Blood 2004, 104, 1450-1458.
86. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA 2006, 103, 14901-14906.
87. Eberhard, Y.; McDermott, S.P.; Wang, X.; Gronda, M.; Venugopal, A.; Wood, T.E.; Hurren, R.; Datti, A.; Batey, R.A.; Wrana, J. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009, 114, 3064-3073.
88. Roth, M.; Will, B.; Simkin, G.; Narayanagari, S.; Barreyro, L.; Bartholdy, B.; Tamari, R.; Mitsiades, C.S.; Verma, A.; Steidl, U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 2012, 120, 386-394.
89. Anastas, J.N.; Moon, R.T. Wnt signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 2013, 13, 11-26.
90. Nelson, R.L. Iron and colorectal cancer risk: Human studies. Nutr. Rev. 2001, 59, 140-148.
91. Chua, A.C.; Klopcic, B.; Lawrance, I.C.; Olynyk, J.K.; Trinder, D. Iron: An emerging factor in colorectal carcinogenesis. World J. Gastroenterol. 2010, 16, 663-672.
92. Brooks, B.E.; Buchanan, S.K. Signaling mechanisms for activation of extracytoplasmic function (ecf) sigma factors. Biochim. Biophys. Acta 2008, 1778, 1930-1945.
93. Song, S.; Christova, T.; Perusini, S.; Alizadeh, S.; Bao, R.Y.; Miller, B.W.; Hurren, R.; Jitkova, Y.; Gronda, M.; Isaac, M. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res. 2011, 71, 7628-7639.
94. Coombs, G.S.; Schmitt, A.A.; Canning, C.A.; Alok, A.; Low, I.C.; Banerjee, N.; Kaur, S.; Utomo, V.; Jones, C.M.; Pervaiz, S. Modulation of wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 2012, 31, 213-225.
95. Daniels, T.R.; Bernabeu, E.; Rodriguez, J.A.; Patel, S.; Kozman, M.; Chiappetta, D.A.; Holler, E.; Ljubimova, J.Y.; Helguera, G.; Penichet, M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 2012, 1820, 291-317.
96. Ohgami, R.S.; Campagna, D.R.; McDonald, A.; Fleming, M.D. The steap proteins are metalloreductases. Blood 2006, 108, 1388-1394.
97. Gomes, I.M.; Maia, C.J.; Santos, C.R. Steap proteins: From structure to applications in cancer therapy. Mol. Cancer Res. 2012, 10, 573-587.
98. Grunewald, T.G.; Bach, H.; Cossarizza, A.; Matsumoto, I. The steap protein family: Versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions. Biol. Cell 2012, 104, 641-657.
99. Becton, D.L.; Roberts, B. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res. 1989, 49, 4809-4812.
100. Noulsri, E.; Richardson, D.R.; Lerdwana, S.; Fucharoen, S.; Yamagishi, T.; Kalinowski, D.S.; Pattanapanyasat, K. Antitumor activity and mechanism of action of the iron chelator, dp44mt, against leukemic cells. Am. J. Hematol. 2009, 84, 170-176.
101. Callens, C.; Coulon, S.; Naudin, J.; Radford-Weiss, I.; Boissel, N.; Raffoux, E.; Wang, P.H.; Agarwal, S.; Tamouza, H.; Paubelle, E. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J. Exp. Med. 2010, 207, 731-750.
102. Rodriguez, J.A.; Luria-Perez, R.; Lopez-Valdes, H.E.; Casero, D.; Daniels, T.R.; Patel, S.; Avila, D.; Leuchter, R.; So, S.; Ortiz-Sanchez, E. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant b cells. Leuk. Lymphoma 2011, 52, 2169-2178.
103. Fukushima, T.; Kawabata, H.; Nakamura, T.; Iwao, H.; Nakajima, A.; Miki, M.; Sakai, T.; Sawaki, T.; Fujita, Y.; Tanaka, M. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res. 2011, 31, 1741-1744.
104. Estrov, Z.; Tawa, A.; Wang, X.H.; Dube, I.D.; Sulh, H.; Cohen, A.; Gelfand, E.W.; Freedman, M.H. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987, 69, 757-761.
105. Yee, K.W.; Cortes, J.; Ferrajoli, A.; Garcia-Manero, G.; Verstovsek, S.; Wierda, W.; Thomas, D.; Faderl, S.; King, I.; O'Brien, S.M. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk. Res. 2006, 30, 813-822.
106. Choi, J.G.; Kim, J.L.; Park, J.; Lee, S.; Park, S.J.; Kim, J.S.; Choi, C.W. Effects of oral iron chelator deferasirox on human malignant lymphoma cells. Korean J. Hematol. 2012, 47, 194-201.
107. Vazana-Barad, L.; Granot, G.; Mor-Tzuntz, R.; Levi, I.; Dreyling, M.; Nathan, I.; Shpilberg, O. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leuk. Lymphoma 2013, 54, 851-859.
108. Maris, J.M. Recent advances in neuroblastoma. N. Engl. J. Med. 2010, 362, 2202-2211.
109. Blatt, J. Deferoxamine in children with recurrent neuroblastoma. Anticancer Res. 1994, 14, 2109-2112.
110. Chaston, T.B.; Lovejoy, D.B.; Watts, R.N.; Richardson, D.R. Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9, 402-414.
111. Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M.A.; Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 1990, 50, 4929-4930.
112. Donfrancesco, A.; de Bernardi, B.; Carli, M.; Mancini, A.; Nigro, M.; de Sio, L.; Casale, F.; Bagnulo, S.; Helson, L.; Deb, G. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary results. Italian neuroblastoma cooperative group. Eur. J. Cancer 1995, 31A, 612-615.
113. Lui, G.Y.; Obeidy, P.; Ford, S.J.; Tselepis, C.; Sharp, D.M.; Jansson, P.J.; Kalinowski, D.S.; Kovacevic, Z.; Lovejoy, D.B.; Richardson, D.R. The iron chelator, deferasirox, as a novel strategy for cancer treatment: Oral activity against human lung tumor xenografts and molecular mechanism of action. Mol. Pharmacol. 2013, 83, 179-190.
114. Ford, S.; Obeidy, P.; Lovejoy, D.; Bedford, M.; Nichols, L.; Chadwick, C.; Tucker, O.; Lui, G.; Kalinowski, D.; Jansson, P. Deferasirox (icl670a) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br. J. Pharmacol. 2013, 168, 1316-1328.
115. Dixon, K.M.; Lui, G.Y.; Kovacevic, Z.; Zhang, D.; Yao, M.; Chen, Z.; Dong, Q.; Assinder, S.J.; Richardson, D.R. Dp44mt targets the akt, tgf-beta and erk pathways via the metastasis suppressor ndrg1 in normal prostate epithelial cells and prostate cancer cells. Br. J. Cancer 2013, 108, 409-419.
116. Rao, V.A.; Klein, S.R.; Agama, K.K.; Toyoda, E.; Adachi, N.; Pommier, Y.; Shacter, E.B. The iron chelator dp44mt causes DNA damage and selective inhibition of topoisomerase iiα in breast cancer cells. Cancer Res. 2009, 69, 948-957.